Tamoxifen citrate salt

Specifications / Handling

More Information
Product Details
Synonyms	(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; ICI 46474; Istubal; Kessar; Noltam; Nolvadex; TMX; Valodex; Zemide
Product Type	Chemical
Properties
Formula	C₂₆H₂₉NO . C₆H₈O₇
MW	563.64
CAS	54965-24-1
Purity Chemicals	≥98%
Appearance	White powder.
Solubility	Soluble in DMSO or methanol. Slightly soluble in ethanol.
Identity	Determined by NMR.
Declaration	Manufactured by Chemodex.
Other Product Data	Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key	FQZYTYWMLGAPFJ-OQKDUQJOSA-N
Smiles	CN(CCOC1=CC=C(/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)/CC)C=C1)C.OC(CC(O)(C(O)=O)CC(O)=O)=O
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+20°C
Long Term Storage	+4°C
Handling Advice	Keep cool and dry. Protect from light and moisture.
Use/Stability	Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Selective estrogen receptor modulator (SERM) used as adjuvant therapy for estrogen-dependent breast cancer. Antagonist of ER action in breast tissue and breast cancer cells and ER agonist in bone, uterus, and the cardiovasculature system. This prodrug is metabolized by cytochrome P450 (CYP450) enzymes to the active metabolites N-desmethyl-TMX, 4-hydroxy-N-desmethyl-TMX (endoxifen) and 4-hydroxy-TMX (afimoxifene). N,N-Didesmethyl-4-hydroxytamoxifen (norendoxifen), another active metabolite has been found to act as a potent competitive aromatase inhibitor and may also be involved in its antiestrogenic activity. Binds microsomal antiestrogen binding sites, altering cholesterol esterification at therapeutic doses and impacting breast cancer cell differentiation, apoptosis, and autophagy. Protein kinase C (PKC) inhibitor and anti-angiogenetic factor.

Product References

(1) K. B. Horwitz & W. L. McGuire; J. Biol. Chem. 253, 8185 (1978) | (2) V.C. Jordan, et al.; Cancer Treat. Rep. 64, 745 (1980) | (3) C.A. O'Brian, et al.; Cancer Res. 45, 2462 (1985) | (4) K.J. Edwards, et al.; J. Med. Chem. 35, 2753 (1992) | (5) M. Clarke, et al.; Lancet 351, 1451 (1998) | (6) D.A. Tonetti & V.C. Jordan; Mol. Med. Today 2, 218 (1996) | (7) J.M. Hall, et al.; J. Biol. Chem. 276, 36869 (2001) | (8) P. Thomas, et al.; Endocrinol. 146, 624 (2005) | (9) M.S. Singh, et al.; Breast 20, 111 (2011) | (10) P. de Medina, et al.; Chem. Phys. Lip. 164, 432 (2011) | (11) V.K. Todorova, et al.; Cancer Chemother. Pharmacol. 67, 285 (2011)

Call	+41 61 926 6040
Fax	+41 61 926 6049